ArticleDrug safety2026
Consumer Views on the Role of the Natural Health Products (NHPs) Industry in Pharmacovigilance for NHPs: A Qualitative Study in New Zealand.
Article in Drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionPharmacovigilance (safety monitoring) for natural health products (NHPs) is essential for consumer health protection. However, pharmacovigilance for NHPs is under-researched, especially regarding consumer involvement and the contributions of the NHPs industry.
objectivesThis qualitative study aimed to explore consumers' views, experiences, and awareness of the NHPs industry's contributions to pharmacovigilance for NHPs in New Zealand.
methodsOne-on-one online interviews were conducted with NHP consumers (n = 19) using a semi-structured interview schedule with the following domains: (1) meaning of terms (NHPs and pharmacovigilance); (2) pharmacovigilance for NHPs (including experiences with reporting adverse drug reactions (ADRs) to the NHPs industry); (3) views on NHP regulations and pharmacovigilance regulatory requirements for the NHPs industry; (4) a proposed active surveillance study for NHPs. Interviews were recorded, transcribed verbatim, and analysed inductively.
resultsFive main themes were identified: (1) right to choose; (2) trust enables engagement; (3) considering information; (4) rationalising consumer protection; (5) perceiving and navigating risk. Participants exercised autonomy to self-select NHPs. Participants had limited experience with ADRs (associated with NHP use) and with reporting ADRs to the NHPs industry. Despite acknowledging that ethical standards varied across companies, participants expressed distrust of the industry's handling of ADRs, due to perceived conflicts of interest and a lack of transparency. Participants' self-responsibility, underscored by autonomy and lack of trust in the industry, appeared to be significant barriers to the industry's involvement in pharmacovigilance for NHPs. Despite low awareness of NHP regulations, participants held expectations for regulatory requirements that balance product accessibility and safety controls.
conclusionParticipants (consumers of NHPs) had minimal engagement with the NHPs industry regarding pharmacovigilance. Raising awareness of the potential harms associated with NHP use, improving knowledge of channels for reporting ADRs, and fostering trust in the industry's handling of ADR reports could empower consumers and enable the industry to assume a more active and significant role in pharmacovigilance for NHPs. Quantitative studies involving larger samples of NHP consumers are necessary to corroborate these findings.
Identifiers
42827217What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.